Skip to main content
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc — Investor Relations & Filings

Ticker · XFOR ISIN · US0428731097 LEI · 549300R0UFVPXWP86U94 US Manufacturing
Open in API
Filings indexed 784 across all filing types
Latest filing 2019-04-12 Capital/Financing Update
Country US United States of America
Listing US XFOR

About X4 Pharmaceuticals, Inc

https://www.x4pharma.com/

X4 Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company that develops and commercializes therapies for rare diseases of the immune system. The company focuses on diseases resulting from the dysfunction of the CXCR4 pathway, a key signaling pathway for immune cell trafficking. Its lead product, XOLREMDI™ (mavorixafor), is an oral, selective antagonist of the CXCR4 receptor. It is approved for use in patients aged 12 and older with WHIM syndrome (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) to increase the number of circulating neutrophils and lymphocytes. The company's pipeline includes further investigation of mavorixafor for other chronic neutropenic disorders.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a preliminary prospectus supplement filed pursuant to Rule 424(b)(5) related to a securities offering. It includes detailed information about the offering of common stock, pre-funded warrants, and Class A warrants, including pricing, underwriting, risk factors, and use of proceeds. The document is a registration and offering prospectus supplement, which is a capital markets document related to fundraising activities. It is not a financial report, earnings release, management discussion, or any other type of corporate report. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, consistent with a capital raising filing.
2019-04-12 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes a settlement agreement and updated business description and risk factors, but does not contain comprehensive financial statements or detailed financial performance data. The document length is 3972 characters, which is relatively short and typical for an 8-K filing. The nature of the content and the form type clearly indicate this is a Regulatory Filing (RNS) rather than a full report like an Annual Report (10-K) or Interim Report (IR).
2019-04-11 English
FORM 4/A SUBMISSION
Director's Dealing
2019-04-03 English
FORM 4/A SUBMISSION
Director's Dealing
2019-04-03 English
FORM 4/A SUBMISSION
Director's Dealing
2019-04-03 English
FORM 4 SUBMISSION
Director's Dealing
2019-04-03 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.